-4%
Zoledronic Acid belongs to the bisphosphonate class and primarily targets bones. It inhibits osteoclast-mediated bone resorption due to its high affinity for mineralized bone. After intravenous administration, it rapidly localizes at areas of high bone turnover. Zoledronic Acid’s main target is the enzyme farnesyl pyrophosphate synthase in osteoclasts. Its long-lasting effect is due to its strong binding to bone minerals.
Aclasta is used for the following conditions:
- Postmenopausal Osteoporosis: For treatment and prevention.
- Osteoporosis in Men: To increase bone mass.
- Glucocorticoid-Induced Osteoporosis: For treatment and prevention.
- Paget’s Disease of Bone: Treatment in both men and women.
The optimal treatment duration is not fully established. For patients with a low fracture risk, discontinuing the drug after 3–5 years of use should be considered.
Use only as directed by a registered physician.
- Postmenopausal Osteoporosis (Treatment): 5 mg IV infusion yearly (over at least 15 minutes).
- Postmenopausal Osteoporosis (Prevention): 5 mg IV infusion every 2 years (over at least 15 minutes).
- Osteoporosis in Men: 5 mg IV infusion yearly (over at least 15 minutes).
- Glucocorticoid-Induced Osteoporosis: 5 mg IV infusion yearly (over at least 15 minutes).
- Paget’s Disease: Single 5 mg IV infusion (over at least 15 minutes).
Consider re-treatment in cases of relapse or inadequate response, based on serum alkaline phosphatase levels or persistent symptoms.
- For Paget’s Disease: Patients should take 1500 mg of elemental calcium daily in divided doses and 800 IU of vitamin D, especially during the two weeks following treatment.
- For Osteoporosis: Supplemental calcium (at least 1200 mg daily) and vitamin D (800-1000 IU daily) are recommended if dietary intake is insufficient.